cefepime


Also found in: Medical, Wikipedia.
Related to cefepime: Cefixime

cef·e·pime

 (sĕf′ə-pēm′)
n.
A broad-spectrum cephalosporin antibiotic, C19H24N6O5S2, used in its hydrochloride form to treat a variety of infections, including skin and urinary tract infections and certain types of pneumonia.

[cef(a)- + probably (m)e(thyl) + p(yrrole) + (ox)ime.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Translations

cefepime

n cefepima
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
The combination of enmetazobactam with cefepime is currently in late stage of a global Phase 3 development for the treatment of complicated urinary tract infections, including acute pyelonephritis, by Gram-negative bacteria.
The company believes that VNRX-5133, in a fixed combination with the fourth generation cephalosporin, cefepime, has the potential to provide a valuable broad-spectrum treatment option to meet unmet medical needs in patients with infections due to carbapenem-resistant pathogens including carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa, suspected polymicrobial infections caused by both gram-negative and gram-positive susceptible pathogens, and engineerable bioterror pathogens such as Burkholderia spp.
VenatoRx believes that VNRX-5133, in a fixed combination with the fourth generation cephalosporin, cefepime, has the potential to provide a valuable broad-spectrum treatment option to meet unmet medical needs in patients with infections due to carbapenem-resistant pathogens including carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA), suspected polymicrobial infections caused by both gram-negative and gram-positive susceptible pathogens, and engineerable bioterror pathogens such as Burkholderia spp.
VenatoRx's clinical-stage candidate VNRX-5133, when combined with cefepime, a currently marketed antibiotic, may overcome certain forms of antibiotic resistance.
The study developed statistical methods to predict phenotypic resistance from resistance genes for various combinations of the four bacterial species and the antibiotics gentamicin, tobramycin, ciprofloxacin, levofloxacin, trimethoprim-sulfamethoxazole, ertapenem, imipenem, cefazolin, cefepime, cefotaxime, ceftazidime, ceftriaxone, ampicillin, piperacillin and aztreonam.
The present finding of antibiotic susceptibility pattern was out of 250 cases, antibiotic resistance was, Ampicillin 85.4%, Cefuroxime 60.8%, Ceftazidime 52%, Cefepime 36.4%, Cefoxitin 31.6% and Imipenem 5% only.
El antibiotico mas utilizado fue el imipenem/cilastatina (34.4 %), seguido de la piperacilina/tazobactam y el cefepime, ambos con el 28.1 % y en menor grado la vancomicina (9.4 %) (tabla 1).
Intravenous therapy with vancomycin (1.5 g/d), cefepime (3 g/d), and metronidazole (1,500 mg/d) was initiated, and the patient's fever and consciousness improved.
Antimicrobial agent MIC range ([micro]g/mL) Amikacin 2-64 Cefepime 1-64 Ceftazidime 1-64 Ceftriaxone 1-64 Ciprofloxacin 0.25-128 Colistin 0.25-128 Ertapenem 0.5-8 Gentamicin 1-16 Imipenem 0.25-16 Meropenem 0.25-16 Piperacillin/tazobactam 4-128 Tigecycline 0.5-8 Antimicrobial agent KPC-Kp Amikacin 4 Cefepime [greater than or equal to]64 Ceftazidime 16 Ceftriaxone [greater than or equal to]64 Ciprofloxacin 64 Colistin [greater than or equal to]128 Ertapenem [greater than or equal to]8 Gentamicin [greater than or equal to]16 Imipenem 8 Meropenem [greater than or equal to]16 Piperacillin/tazobactam [greater than or equal to]128 Tigecycline 2 Antimicrobial agent E.
All of the children were hospitalized; they were randomized to CAZ-AVI at age-specific doses or cefepime, less than 2,000 mg/infusion for 72 hours.
The isolates were also tested for resistance to ampicillin, cotrimoxazole, ciprofloxacin, ceftriaxone, doripenem, imipenem, ertapenem, aztreonam, moxifloxacin, cefpirome, cefepime, gatifloxacin, and chloramphenicol by Kirby-Bauer disc diffusion method.